September 20, 2014 9:19 AM ET

Healthcare Equipment and Supplies

Company Overview of Immucor, Inc.

Company Overview

Immucor Inc. and its subsidiaries develop, manufacture, and sell reagents and automated systems used primarily by hospitals, clinical labs, and blood banks in tests to detect and identify certain properties of the cell and serum components of human blood before blood transfusions. The company’s reagent product lines include abo blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and a fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. These are used in tests to...

3130 Gateway Drive

PO Box 5625

Norcross, GA 30091

United States

Founded in 1982

1,090 Employees





Key Executives for Immucor, Inc.

Chief Executive Officer
Age: 60
Chief Financial Officer
Age: 52
Vice President of Operations
Vice President of International Finance
Age: 57
Compensation as of Fiscal Year 2014.

Immucor, Inc. Key Developments

Immucor, Inc., Q4 2014 Fixed Income Call, Sep 04, 2014

Immucor, Inc., Q4 2014 Fixed Income Call, Sep 04, 2014

Immucor, Inc., Q3 2014 Fixed Income Call, Apr 15, 2014

Immucor, Inc., Q3 2014 Fixed Income Call, Apr 15, 2014

Immucor, Inc. Reports Consolidated Earnings Results for the Second Quarter and Cash Flow Results for the Six Months of Fiscal 2014; Provides Earnings Guidance for the Year Fiscal 2014

Immucor, Inc. reported consolidated earnings results for the second quarter and cash flow results for the six months of fiscal 2014. The company's consolidated revenue was $100 million, an increase of 22.1% on a GAAP basis when compared with prior year quarter. The like-for-like basis, revenue grew 3.6% over the prior year quarter. The like-for-like comparison includes LIFECODES in the prior year on a pro forma basis and is adjusted for FX, as well as one more ship cycle in the current year quarter. Adjusted EBITDA, which is EBITDA which has been further adjusted to exclude certain noncash expenses and other adjustments as defined by the company's credit agreement, was $38.5 million for the quarter of fiscal year - for the second quarter of fiscal year 2014, compared with $33.9 million in the prior year quarter, an increase of 13.6%. Therefore, on a like-for-like basis, excluding the impact of ship cycles and FX, adjusted EBITDA increased 2% versus the prior year quarter. Net cash provided by operating activity during the first six months of fiscal year 2014 was $13 million, compared with $8.6 million in the prior year, mainly driven by the improvement in operating income. For the full year fiscal 2014, the company continue to expect modest revenue growth and adjusted EBITDA growth in line with revenue. The company continue to focus on the fundamentals of profitable growth and solid cash flow generation.

Similar Private Companies By Industry

Company Name Region
Soft Tissue Regeneration, Inc. United States
Boston Scientific Scimed, Inc. United States
BioTec Films, LLC United States
Paieon, Inc. United States
Medtox Diagnostics, Inc. United States

Recent Private Companies Transactions

June 2, 2014
Organ-i, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Immucor, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at